Conversant Bio Publishes Guide to Multiple Myeloma

May 20, 2014

E-Book Offers Researchers a Foundation of How the Disease Is Approached in the Real World

HUNTSVILLE, Ala. — Conversant Bio, a global leader in supplying the highest-quality human tissue and viable cell samples, today announced it is publishing a guide about multiple myeloma. The e-book, Researcher’s Guide to Multiple Myeloma: From the Real World to the Lab, is available as a free download at http://www.conversantbio.com/multiple-myeloma-ebook

Multiple myeloma is a hematologic cancer that develops in the marrow of the long bones. Researchers are working toward a cure, and this new e-book provides them with a basic foundation of how the disease is approached in the real world. Features of the guide include:

  • How multiple myeloma is diagnosed
  • The different types of multiple myeloma
  • Labwork results of typical multiple myeloma patients in different stages
  • Treatments and side effects

Furthermore, the e-book also details the challenges faced when studying multiple myeloma, including obtaining quality bone marrow and blood samples that are integral for research.

“Researchers will benefit from this e-book when they are developing the criteria and parameters of their multiple myeloma research,” says Luke Doiron, Chief Commercial Officer of Conversant Bio. “They will gain a new perspective on the disease that is outside the scope of the lab. And if they are in need of high-quality bone marrow and blood samples for their research, they can achieve access to such samples through Conversant Bio.”

To download Researcher’s Guide to Multiple Myeloma: From the Real World to the Lab, visit http://www.conversantbio.com/multiple-myeloma-ebook

Media Contact: Luke Doiron
luke.doiron@conversantbio.com
866-838-2798

About Conversant Bio: Conversant Bio provides researchers around the world with hyper-annotated tissue samples in order to conduct informed, cutting-edge investigations into many of today’s most problematic diseases. With a large prospective collections network of 36 U.S.-based clinical sites and an IRB-reviewed chain of custody quality control system, Conversant Bio provides the highest-quality samples on time and on budget. For additional information about Conversant Bio’s services, visit the company’s website at www.conversantbio.com.

About HudsonAlpha: HudsonAlpha Institute for Biotechnology is a nonprofit institute dedicated to innovating in the field of genomic technology and sciences across a spectrum of biological problems. Its mission is three-fold: sparking scientific discoveries that can impact human health and well-being; fostering biotech entrepreneurship; and encouraging the creation of a genomics-literate workforce and society. The HudsonAlpha biotechnology campus consists of 152 acres nestled within Cummings Research Park, the nation’s second largest research park. Designed to be a hothouse of biotech economic development, HudsonAlpha’s state-of-the-art facilities co-locate scientific researchers with entrepreneurs and educators. The relationships formed on the HudsonAlpha campus allow serendipity to yield results in medicine and agriculture. Since opening in 2008, HudsonAlpha, under the leadership of Dr. Richard M. Myers, a key collaborator on the Human Genome Project, has built a name for itself in genetics and genomics research and biotech education, and boasts 26 biotech companies on campus.